摘要
压力型定量吸入气雾剂(MDI)起效迅速,全身不良反应少,并具有携带方便、价格较低等特点。由于气雾剂中的抛射剂氟氯化碳(CFC)存在严重的环保问题,含CFC的气雾剂已趋于淘汰。近年来一些医药公司研发了CFC的替代品,新一代不含CFC的MDI已应用于临床并取得显著效果,本文综述MDI的临床研究进展。
Pressurized metered dose inhaler（MDI） has been used in clinic due to its rapid onset,less adverse reaction,convenience and lower cost.However,since the chlorofluoro carbon（CFC） existing in MDI is unfriendly to environment,MDI with CFC has been eliminating.In recent years,some pharmaceutical companies have developed the substitute for CFC,and the newer MDI without CFC has had remarkable effect in clinical application.This article reviews the progress of MDI in clinical research.
出处
《世界临床药物》
CAS
2012年第11期697-699,共3页
World Clinical Drug
关键词
定量吸入气雾剂
临床研究
氟氯化碳
metered dose inhaler
clinical research
chlorofluoro carbon
